Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 4, 2026

Dell and Dream Finders Homes have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
Dell and Dream Finders Homes have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – June 4, 2026 – Zacks Equity Research shares Dell Technologies DELL as the Bull of the Day and The Campbell's Company CPB as the Bear of the Day…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Dell Technologies would be an excellent stock for investors to consider given its Zacks Rank #1 (Strong Buy).

    60% confidence

  • Analysts have upwardly adjusted their sales expectations for Dell's current and next fiscal years following the earnings release.

    60% confidence

  • The Campbell's Company is rated Zacks Rank #5 (Strong Sell) with EPS revisions remaining bearish across the board.

    60% confidence

  • The AI opportunity shows no signs of slowing.

    60% confidence

  • Dell AI-optimized servers achieved 760% YoY growth, setting a company record.

    60% confidence

  • CPB shares have continued to see weak action in 2026 and quarterly results have been largely disappointing, with shares facing pressure following its latest earnings release.

    60% confidence

  • Dell Technologies is rated Zacks Rank #1 (Strong Buy) with EPS revisions remaining bullish across the board.

    60% confidence

  • Dell Technologies exceeded the Zacks Consensus EPS estimate by nearly 60% and posted a 23% sales surprise.

    60% confidence

Data points we hold from this source

Dell Technologies · stock price230 percent_ytd_return
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Dell and Dream Finders Homes have been highlighted as Zacks Bull and Bear of the Day — Source | Via News | ViaNews Market